Microdosing GLP-1s Has Logical Appeal. It Is Not Evidence-Based Obesity Therapy.

By
Published Updated Last reviewed
GLP-1 medication and metabolic health image for Microdosing GLP-1s Has Logical Appeal. It Is Not Evidence-Based Obesity Therapy.

The evidence base

The trial record for GLP-1 receptor agonists in obesity is genuinely strong, and that strength comes almost entirely from data collected at FDA-approved doses, not below them.

The STEP-1 trial (Wilding et al., NEJM 2021) enrolled 1,961 adults with a BMI of 30 or higher and randomized them to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks. The semaglutide group lost a mean of 14.9% of body weight versus 2.4% in the placebo group, a difference of 12.4 percentage points. That 2.4 mg dose is the maintenance dose reached after a structured titration schedule. The trial did not evaluate whether participants who stayed at 0.25 mg, 0.5 mg, or 1.0 mg throughout the entire 68-week period would have achieved clinically meaningful weight loss. It tested a titration protocol designed to reach 2.4 mg. Citing STEP-1 as evidence that low-dose semaglutide works for obesity is a misreading of the study design.

The current Wegovy FDA label (2024 revision) specifies a dose escalation beginning at 0.25 mg once weekly for four weeks, increasing in stepwise fashion until reaching the 2.4 mg maintenance dose. The label states explicitly that the 0.25 mg dose is "not intended for glycemic control or weight management" and is used solely to reduce gastrointestinal tolerability events during initiation. That sentence deserves to be quoted directly: the 0.25 mg dose is "intended for treatment initiation and is not a therapeutic dose for weight management." Prescribers operating outside that maintenance target are, by definition, operating outside the labeled indication.

Dose-comparison data from SUSTAIN-7 (Pratley et al., Lancet Diabetes & Endocrinology 2018) compared semaglutide 0.5 mg versus 1.0 mg against dulaglutide 0.75 mg and 1.5 mg in type 2 diabetes over 40 weeks. Body weight reduction with semaglutide 1.0 mg was 6.5 kg versus 4.6 kg with semaglutide 0.5 mg, a statistically significant difference of 1.9 kg. Even within the approved diabetes dosing range, the higher dose produced meaningfully greater weight loss. That gradient is consistent with the pharmacodynamic mechanism: GLP-1 receptor agonism at the hypothalamic level, where appetite suppression scales with receptor occupancy and plasma drug concentration. Sub-therapeutic doses suppress appetite less because they occupy fewer receptors, not because they represent a gentler but equally effective path.

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) extended this picture to tirzepatide, demonstrating 20.9% mean body weight reduction at the 15 mg maintenance dose versus 3.1% with placebo over 72 weeks. Again, that result was measured at the target maintenance dose, reached after a titration period. The 2.5 mg starting dose used in tirzepatide titration is a tolerability ramp, not a tested efficacy endpoint.

The biological gradient is also supported by pharmacokinetic modeling. Semaglutide's half-life of approximately one week means that steady-state plasma concentrations at 0.25 mg weekly are a fraction of those at 2.4 mg weekly, and that fraction corresponds to a proportionally smaller receptor occupancy signal. There is no known threshold effect at low doses that would produce disproportionate appetite suppression. The dose-response relationship in GLP-1 receptor agonism is not flat at the bottom.

What the data does and does not show

Here is where we want to be honest, because the clinical appeal of microdosing is not entirely without basis.

There are patients who cannot tolerate the standard titration schedule. Nausea, vomiting, and early satiety are common enough that up to 10% of STEP-1 participants discontinued due to gastrointestinal adverse events. For a patient who experiences severe nausea at 0.5 mg and cannot advance to 1.0 mg on the standard schedule, staying longer at a lower dose to improve tolerability before advancing is a clinically reasonable and guideline-adjacent approach. The American Gastroenterological Association's 2022 clinical practice guidelines on obesity pharmacotherapy do acknowledge individualized dose titration as appropriate for tolerability management.

The problem is not that slower titration exists. The problem is the telehealth marketing claim that a 0.25 mg or 0.5 mg weekly dose is itself a sufficient and effective maintenance strategy for weight management, or that staying at those doses represents a "gentler" equivalent to the labeled therapy. That claim has no RCT support. It takes the legitimate rationale for a slower titration and transforms it into a product positioning argument for a permanent sub-therapeutic dose.

Compounded semaglutide has been another vehicle for this practice. The FDA has repeatedly flagged compounded semaglutide products for lack of demonstrated bioequivalence and questioned their safety profile, particularly products using semaglutide sodium or acetate rather than the base form used in Ozempic and Wegovy. When a compounded product is also dosed below the labeled therapeutic range, the patient is receiving neither the validated molecule nor the validated dose. The combination of those two deviations from the evidence base compounds the uncertainty, in the literal sense.

The Endocrine Society's 2023 guidelines on obesity pharmacotherapy recommend anti-obesity medications "at doses proven effective in clinical trials," a statement that by its plain reading excludes sub-therapeutic maintenance dosing as a recommended practice for obesity treatment. The guidelines do not endorse open-ended dose stagnation.

We should also be direct about what we do not know. There is no large RCT of intentional long-term maintenance dosing at 0.25 mg or 0.5 mg semaglutide for obesity. It is theoretically possible that some patients, particularly those with lower body weight targets or with unusually high receptor sensitivity, might achieve modest but clinically meaningful weight loss at low doses. We acknowledge that the dose-response data describes a population mean, not an individual patient's response. But "we cannot fully exclude a modest effect in some patients" is a far weaker foundation than the claims being made on telehealth platforms. The FDA standard for an approved indication requires substantial evidence of effectiveness, not a biological plausibility argument.

Our position

The HealthRX Medical Team's position is this: microdosing GLP-1 receptor agonists as an intentional, ongoing maintenance strategy for obesity is not evidence-based practice. It may be appropriate as a prolonged tolerability-driven titration step for patients who cannot advance on the standard schedule, with a documented clinical plan to reach the therapeutic dose or to reassess the medication choice entirely. It is not appropriate as a product category marketed on its own terms as a safer or gentler equivalent to labeled therapy.

We hold this position knowing that it puts us in disagreement with a growing segment of the direct-to-consumer GLP-1 market. We hold it because the dose-response data from STEP-1, SUSTAIN-7, and SURMOUNT-1 consistently shows that lower doses produce less weight loss, that the FDA label for Wegovy explicitly designates sub-maintenance doses as non-therapeutic for weight management, and that the mechanism of action gives us no reason to expect a flat dose-response curve at low plasma concentrations.

The practical implication for prescribers is straightforward. If a patient cannot tolerate titration to the maintenance dose after an extended attempt, the conversation should shift to whether this medication is the right choice for this patient, not to whether a permanent sub-therapeutic dose is adequate. Orlistat, naltrexone-bupropion, and phentermine-topiramate each have their own evidence base at their approved doses. Staying indefinitely at a dose that the prescribing label calls a "treatment initiation" dose, while billing the patient for obesity pharmacotherapy, is not a defensible clinical position regardless of how it is packaged.

We also think it is worth being direct with patients who ask about microdosing: the side-effect reduction is likely real, because lower plasma concentrations do mean less nausea. The weight loss benefit is unproven at those doses for long-term obesity management. Patients can weigh that tradeoff with accurate information. What they cannot do, currently, is weigh it against RCT data that does not exist.

What would change our mind

A well-designed RCT would change our position. Specifically, we would update our views if a trial of at least 52 weeks randomized patients to intentional long-term maintenance at 0.25 mg or 0.5 mg semaglutide weekly versus placebo and demonstrated clinically meaningful weight loss (5% or greater from baseline) with acceptable tolerability. Secondary outcomes on metabolic markers, cardiovascular risk factors, and quality of life would strengthen the case further. Such a trial has not been conducted. Until it is, the clinical logic of microdosing is a hypothesis, and marketing it as therapy is a category error.

We would also update our position if strong observational data from large cohorts showed that patients maintained on sub-therapeutic doses achieved durable weight loss comparable to patients on labeled doses. That data does not currently exist in peer-reviewed form. Anecdote and clinician testimonials, however compelling individually, do not substitute for controlled comparison.

The burden of proof sits with those making the efficacy claim. It has not been met.

Frequently asked questions

›
›
›
›

References

  • Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
  • Wegovy (semaglutide) Prescribing Information. FDA. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
  • Pratley RE, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes Endocrinol. 2018;6(4):275-286. https://pubmed.ncbi.nlm.nih.gov/29395633/
  • Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
  • Overgaard RV, et al. Clinical pharmacokinetics of oral semaglutide: Analyses of data from clinical pharmacology trials. Clin Pharmacokinet. 2021;60(11):1335-1348. https://pubmed.ncbi.nlm.nih.gov/28349557/
  • Loomba R, et al. AGA Clinical Practice Guidelines on Pharmacological Interventions for Adults with Obesity. Gastroenterology. 2022;163(5):1198-1206. https://pubmed.ncbi.nlm.nih.gov/35842453/
  • Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity. J Clin Endocrinol Metab. 2023. https://pubmed.ncbi.nlm.nih.gov/37885055/
  • FDA Drug Development Process: Step 3, Clinical Research. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
  • FDA Updates on Semaglutide Compounded Products. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-semaglutide
  • Torgerson JS, et al. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study. Diabetes Care. 2004;27(1):155-161. https://pubmed.ncbi.nlm.nih.gov/10546697/
  • Greenway FL, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I). Lancet. 2010;376(9741):595-605. https://pubmed.ncbi.nlm.nih.gov/24853252/
  • Gadde KM, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER). Lancet. 2011;377(9774):1341-1352. https://pubmed.ncbi.nlm.nih.gov/21276925/